To address the challenges associated with poor bioavailability, we have developed a programme of technologies aimed at improving drug solubility and permeability.
Our Highway to clinic platform streamlines development by assessing a range of advanced formulation technologies to overcome bioavailability and stability challenges.
By delivering the API in a dissolved state, absorption can be accelerated through the elimination of the dissolution step. Our formulation experts apply proven solubility enhancement strategies—including salt formation and the incorporation of surfactants, complexing agents, and co-solvents—to improve the performance of poorly soluble drug candidates.
Micronisation and nanonisation increase drug surface area, accelerating dissolution and improving bioavailability. Eurofins CDMO offers extensive expertise in wet milling and nanosuspension stabilisation to enhance the performance of poorly soluble APIs.
Lipid-based delivery systems leverage carefully selected lipids, surfactants, and co-solvents to improve drug solubility and absorption. Among these, Self-Emulsifying Drug Delivery Systems (SEDDS) offer a proven approach to enhancing bioavailability by forming fine emulsions in the gastrointestinal tract, promoting effective drug solubilisation and uptake.
Amorphous Solid Dispersions (ASDs) are a proven formulation strategy for enhancing the bioavailability of poorly water-soluble drug candidates. By dispersing the API within a polymer matrix and maintaining it in an amorphous state, ASDs improve solubility, accelerate dissolution, and support increased drug absorption. At Eurofins CDMO, we offer extensive expertise in ASD development and manufacturing, utilising advanced spray-drying and bead-coating technologies to optimise drug product performance.